Features that predict responsiveness to chemotherapy and endocrine therapies
- 1 August 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10, 147-157
- https://doi.org/10.1016/s0960-9776(16)30024-8
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Adjuvant Therapy for Very Young Women With Breast Cancer: Need for Tailored TreatmentsJNCI Monographs, 2001
- Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized TrialsJournal of Clinical Oncology, 2001
- A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the dataStatistics in Medicine, 2000
- Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized StudyJNCI Journal of the National Cancer Institute, 2000
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000
- Subsets within the chemotherapy overviewThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.Journal of Clinical Oncology, 1997
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992